nach oben

CNS Drugs

Erschienen in:

01.07.2011 | Leading Article

Enhancing CNS Repair in Neurological Disease

Challenges Arising from Neurodegeneration and Rewiring of the Network

verfasst von: Xiaohua Xu, Arthur E. Warrington, Allan J. Bieber, Moses Rodriguez

Erschienen in: CNS Drugs | Ausgabe 7/2011

Einloggen, um Zugang zu erhalten

Abstract

Repair of the central nervous system (CNS) constitutes an integral part of treating neurological disease and plays a crucial role in restoring CNS architecture and function. Distinct strategies have been developed to reconstruct the damaged neural tissue, with many tested preclinically in animal models. We review cell replacement-based repair strategies. By taking spinal cord injury, cerebral ischaemia and degenerative CNS disorders as examples for CNS repair, we discuss progress and potential problems in utilizing embryonic stem cells and adult neural/non-neural stem cells to repair cell loss in the CNS. Nevertheless, CNS repair is not simply a matter of cell transplantation. The major challenge is to induce regenerating neural cells to integrate into the neural network and compensate for damaged neural function. The neural cells confront an environment very different from that of the developmental stage in which these cells differentiate to form interwoven networks.

During the repair process, one of the challenges is neurodegeneration, which can develop from interrupted innervations to/from the targets, chronic inflammation, ischaemia, aging or idiopathic neural toxicity. Neurodegeneration, which occurs on the basis of a characteristic vascular and neural web, usually presents as a chronically progressive process with unknown aetiology. Currently, there is no effective treatment to stop or slow down neurodegeneration. Pathological changes from patients with Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis indicate a broken homeostasis in the CNS. We discuss how the blood-brain barrier and neural networks are formed to maintain CNS homeostasis and their contribution to neurodegeneration in diseased conditions.

Another challenge is that some inhibitors produced by CNS injury do not facilitate the regenerating neural cells to incorporate into a pre-existing network. We review glial responses to CNS injury. Of note, the reactive astrocytes not only encompass the lesions/pathogens but may also form glial scars to impede regenerating axons from traversing the lesions. In addition, myelin debris can prevent axon growth. Myelination enables saltatory transduction of electrical impulses along axonal calibers and actually provides trophic support to stabilize the axons. Therefore, repair strategies should be designed to promote axonal growth, myelination and modulate astrocytic responses. Finally, we discuss recent progress in developing human monoclonal IgMs that regulate CNS homeostasis and promote neural regeneration.

Hagg T, Oudega M. Degenerative and spontaneous regenerative processes after spinal cord injury. J Neurotrauma 2006 Mar–Apr; 23(3–4): 264–80PubMed

Silver J, Miller JH. Regeneration beyond the glial scar. Nat Rev Neurosci 2004 Feb; 5(2): 146–56PubMedCrossRef

Lo EH. A new penumbra: transitioning from injury into repair after stroke. Nat Med 2008 May; 14(5): 497–500PubMedCrossRef

LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer’s disease. Nat Rev Neurosci 2007 Jul; 8(7): 499–509PubMedCrossRef

Daniela F, Vescovi AL, Bottai D. The stem cells as a potential treatment for neurodegeneration. Methods Mol Biol 2007; 399: 199–213PubMedCrossRef

Leker RR, Lasri V, Chernoguz D. Growth factors improve neurogenesis and outcome after focal cerebral ischemia. J Neural Transm 2009 Nov; 116(11): 1397–402PubMedCrossRef

Sahni V, Kessler JA. Stem cell therapies for spinal cord injury. Nat Rev Neurol 2010 Jul; 6(7): 363–72PubMedCrossRef

McDonald JW, Liu XZ, Qu Y, et al. Transplanted embryonic stem cells survive, differentiate and promote recovery in injured rat spinal cord. Nat Med 1999 Dec; 5(12): 1410–2PubMedCrossRef

Erdo F, Buhrle C, Blunk J, et al. Host-dependent tumorigenesis of embryonic stem cell transplantation in experimental stroke. J Cereb Blood Flow Metab 2003 Jul; 23(7): 780–5PubMed

10.

Bjorklund LM, Sanchez-Pernaute R, Chung S, et al. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci U S A 2002 Feb 19; 99(4): 2344–9PubMedCrossRef

11.

Lee SH, Lumelsky N, Studer L, et al. Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells. Nat Biotechnol 2000 Jun; 18(6): 675–9PubMedCrossRef

12.

Eriksson PS, Perfilieva E, Bjork-Eriksson T, et al. Neurogenesis in the adult human hippocampus. Nat Med 1998 Nov; 4(11): 1313–7PubMedCrossRef

13.

Toda H, Takahashi J, Iwakami N, et al. Grafting neural stem cells improved the impaired spatial recognition in ischemic rats. Neurosci Lett 2001 Dec 4; 316(1): 9–12PubMedCrossRef

14.

Shim JW, Park CH, Bae YC, et al. Generation of functional dopamine neurons from neural precursor cells isolated from the subventricular zone and white matter of the adult rat brain using Nurr1 overexpression. Stem Cells 2007 May; 25(5): 1252–62PubMedCrossRef

15.

Bonner JF, Blesch A, Neuhuber B, et al. Promoting directional axon growth from neural progenitors grafted into the injured spinal cord. J Neurosci Res May 1; 88(6): 1182-92

16.

Chen J, Li Y, Wang L, et al. Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke 2001 Apr; 32(4): 1005–11PubMedCrossRef

17.

Newman MB, Davis CD, Kuzmin-Nichols N, et al. Human umbilical cord blood (HUCB) cells for central nervous system repair. Neurotox Res 2003; 5(5): 355–68PubMedCrossRef

18.

Sykova E, Homola A, Mazanec R, et al. Autologous bone marrow transplantation in patients with subacute and chronic spinal cord injury. Cell Transplant 2006; 15(8–9): 675–87PubMedCrossRef

19.

Munoz-Elias G, Marcus AJ, Coyne TM, et al. Adult bone marrow stromal cells in the embryonic brain: engraftment, migration, differentiation, and long-term survival. J Neurosci 2004 May 12; 24(19): 4585–95PubMedCrossRef

20.

Pluchino S, Zanotti L, Rossi B, et al. Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism. Nature 2005 Jul 14; 436(7048): 266–71PubMedCrossRef

21.

Martino G, Pluchino S. The therapeutic potential of neural stem cells. Nat Rev Neurosci 2006 May; 7(5): 395–406PubMedCrossRef

22.

Ming GL, Song H. Adult neurogenesis in the mammalian central nervous system. Annu Rev Neurosci 2005; 28: 223–50PubMedCrossRef

23.

Arvidsson A, Collin T, Kirik D, et al. Neuronal replacement from endogenous precursors in the adult brain after stroke. Nat Med 2002 Sep; 8(9): 963–70PubMedCrossRef

24.

Hamilton LK, Truong MK, Bednarczyk MR, et al. Cellular organization of the central canal ependymal zone, a niche of latent neural stem cells in the adult mammalian spinal cord. Neuroscience 2009 Dec 15; 164(3): 1044–56PubMedCrossRef

25.

Bath KG, Lee FS. Neurotrophic factor control of adult SVZ neurogenesis. Dev Neurobiol 2010 Apr; 70(5): 339–49PubMed

26.

Case LC, Tessier-Lavigne M. Regeneration of the adult central nervous system. Curr Biol 2005 Sep 20; 15(18): R749–53PubMedCrossRef

27.

Bredesen DE, Rao RV, Mehlen P. Cell death in the nervous system. Nature 2006 Oct 19; 443(7113): 796–802PubMedCrossRef

28.

Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005 Aug 15; 202(4): 473–7PubMedCrossRef

29.

Frank-Cannon TC, Alto LT, McAlpine FE, et al. Does neuroinflammation fan the flame in neurodegenerative diseases? Mol Neurodegener 2009; 4: 47PubMedCrossRef

30.

Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders. Nat Rev Neurosci 2007 Sep; 8(9): 663–72PubMedCrossRef

31.

Auluck PK, Caraveo G, Lindquist S. α-Synuclein: membrane interactions and toxicity in Parkinson’s disease. Annu Rev Cell Dev Biol 2010 Nov 10; (26): 211-33

32.

Ilieva H, Polymenidou M, Cleveland DW. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol 2009 Dec 14; 187(6): 761–72PubMedCrossRef

33.

Glass CK, Saijo K, Winner B, et al. Mechanisms underlying inflammation in neurodegeneration. Cell 2010 Mar 19; 140(6): 918–34PubMedCrossRef

34.

Wyss-Coray T, Loike JD, Brionne TC, et al. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat Med 2003 Apr; 9(4): 453–7PubMedCrossRef

35.

Tan L, Gordon KB, Mueller JP, et al. Presentation of proteolipid protein epitopes and B7-1-dependent activation of encephalitogenic T cells by IFN-gamma-activated SJL/J astrocytes. J Immunol 1998 May 1; 160(9): 4271–9PubMed

36.

Constantinescu CS, Tani M, Ransohoff RM, et al. Astrocytes as antigen-presenting cells: expression of IL-12/ IL-23. J Neurochem 2005 Oct; 95(2): 331–40PubMedCrossRef

37.

Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998 Jan 29; 338(5): 278–85PubMedCrossRef

38.

Rodriguez M, Scheithauer B. Ultrastructure of multiple sclerosis. Ultrastruct Pathol 1994 Jan–Apr; 18(1–2): 3–13PubMedCrossRef

39.

Minghetti L. Role of inflammation in neurodegenerative diseases. Curr Opin Neurol 2005 Jun; 18(3): 315–21PubMedCrossRef

40.

Fugger L, Friese MA, Bell JI. From genes to function: the next challenge to understanding multiple sclerosis. Nat Rev Immunol 2009 Jun; 9(6): 408–17PubMedCrossRef

41.

Beleza-Meireles A, Al-Chalabi A. Genetic studies of amyotrophic lateral sclerosis: controversies and perspectives. Amyotroph Lateral Scler 2009 Feb; 10(1): 1–14PubMedCrossRef

42.

Lesage S, Brice A. Parkinson’s disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet 2009 Apr 15; 18(R1): R48–59PubMedCrossRef

43.

Ertekin-Taner N. Genetics of Alzheimer disease in the pre-and post-GWAS era. Alzheimers Res Ther 2010; 2(1): 3PubMedCrossRef

44.

Goate AM, Haynes AR, Owen MJ, et al. Predisposing locus for Alzheimer’s disease on chromosome 21. Lancet 1989 Feb 18; 1(8634): 352–5PubMedCrossRef

45.

Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature 1991 Feb 21; 349(6311): 704–6PubMedCrossRef

46.

Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature 1995 Jun 29; 375(6534): 754–60PubMedCrossRef

47.

Levy-Lahad E, Wijsman EM, Nemens E, et al. A familial Alzheimer’s disease locus on chromosome 1. Science 1995 Aug 18; 269(5226): 970–3PubMedCrossRef

48.

Rogaev EI, Sherrington R, Rogaeva EA, et al. Familial Alzheimer’s disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer’s disease type 3 gene. Nature 1995 Aug 31; 376(6543): 775–8PubMedCrossRef

49.

Bertram L, Tanzi RE. Genome-wide association studies in Alzheimer’s disease. Hum Mol Genet 2009 Oct 15; 18(R2): R137–45PubMedCrossRef

50.

Borchelt DR, Thinakaran G, Eckman CB, et al. Familial Alzheimer’s disease-linked presenilin 1 variants elevate Abeta 1-42/1-40 ratio in vitro and in vivo. Neuron 1996 Nov; 17(5): 1005–13PubMedCrossRef

51.

Xia W, Zhang J, Kholodenko D, et al. Enhanced production and oligomerization of the 42-residue amyloid beta-protein by Chinese hamster ovary cells stably expressing mutant presenilins. J Biol Chem 1997 Mar 21; 272(12): 7977–82PubMedCrossRef

52.

Holtzman DM, Bales KR, Tenkova T, et al. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A 2000 Mar 14; 97(6): 2892–7PubMedCrossRef

53.

Baulac S, LaVoie MJ, Kimberly WT, et al. Functional gamma-secretase complex assembly in Golgi/trans-Golgi network: interactions among presenilin, nicastrin, Aph1, Pen-2, and gamma-secretase substrates. Neurobiol Dis 2003 Nov; 14(2): 194–204PubMedCrossRef

54.

Dion PA, Daoud H, Rouleau GA. Genetics of motor neuron disorders: new insights into pathogenic mechanisms. Nat Rev Genet 2009 Nov; 10(11): 769–82PubMedCrossRef

55.

Tam SJ, Watts RJ. Connecting vascular and nervous system development: angiogenesis and the blood-brain barrier. Annu Rev Neurosci 2010; 33: 379–408PubMedCrossRef

56.

Begley DJ, Brightman MW. Structural and functional aspects of the blood-brain barrier. Prog Drug Res 2003; 61: 39–78PubMed

57.

Zlokovic BV, Apuzzo ML. Strategies to circumvent vascular barriers of the CNS. Neurosurgery 1998; 43(4): 877–8PubMedCrossRef

58.

Schlageter KE, Molnar P, Lapin GD, et al. Microvessel organization and structure in experimental brain tumors: microvessel populations with distinctive structural and functional properties. Microvasc Res 1999 Nov; 58(3): 312–28PubMedCrossRef

59.

Banerjee S, Bhat MA. Neuron-glial interactions in blood-brain barrier formation. Annu Rev Neurosci 2007; 30: 235–58PubMedCrossRef

60.

Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006 Jan; 7(1): 41–53PubMedCrossRef

61.

Rouach N, Glowinski J, Giaume C. Activity-dependent neuronal control of gap-junctional communication in astrocytes. J Cell Biol 2000 Jun 26; 149(7): 1513–26PubMedCrossRef

62.

Rouach N, Koulakoff A, Abudara V, et al. Astroglial metabolic networks sustain hippocampal synaptic transmission. Science 2008 Dec 5; 322(5907): 1551–5PubMedCrossRef

63.

Bushong EA, Martone ME, Jones YZ, et al. Protoplasmic astrocytes in CA1 stratum radiatum occupy separate anatomical domains. J Neurosci 2002 Jan 1;22(1): 183–92PubMed

64.

Khuth ST, Strazielle N, Giraudon P, et al. Impairment of blood-cerebrospinal fluid barrier properties by retrovirus-activated T lymphocytes: reduction in cerebrospinal fluid-to-blood efflux of prostaglandin E 2. J Neurochem 2005 Sep; 94(6): 1580–93PubMedCrossRef

65.

Navikas V, Link H. Review: cytokines and the pathogenesis of multiple sclerosis. J Neurosci Res 1996 Aug 15; 45(4): 322–33PubMedCrossRef

66.

Nave KA, Trapp BD. Axon-glial signaling and the glial support of axon function. Annu Rev Neurosci 2008; 31: 535–61PubMedCrossRef

67.

Rakic P, Ayoub AE, Breunig JJ, et al. Decision by division: making cortical maps. Trends Neurosci 2009 May; 32(5): 291–301PubMedCrossRef

68.

Sofroniew MV, Vinters HV. Astrocytes: biology and pathology. Acta Neuropathol 2010 Jan; 119(1): 7–35PubMedCrossRef

69.

Baumann N, Pham-Dinh D. Biology of oligodendrocyte and myelin in the mammalian central nervous system. Physiol Rev 2001 Apr; 81(2): 871–927PubMed

70.

Black JA, Waxman SG. The perinodal astrocyte. Glia 1988; 1(3): 169–83PubMedCrossRef

71.

Ransohoff RM, Perry VH. Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol 2009; 27: 119–45PubMedCrossRef

72.

Lindvall O, Kokaia Z. Prospects of stem cell therapy for replacing dopamine neurons in Parkinson’s disease. Trends Pharmacol Sci 2009 May; 30(5): 260–7PubMedCrossRef

73.

Sofroniew MV. Molecular dissection of reactive astro-gliosis and glial scar formation. Trends Neurosci 2009 Dec; 32(12): 638–47PubMedCrossRef

74.

Margolis RK, Margolis RU. Nervous tissue proteoglycans. EXS 1994; 70: 145–77PubMed

75.

Yamagata T, Saito H, Habuchi O, et al. Purification and properties of bacterial chondroitinases and chon-drosulfatases. J Biol Chem 1968 Apr 10; 243(7): 1523–35PubMed

76.

Bradbury EJ, Carter LM. Manipulating the glial scar: chondroitinase ABC as a therapy for spinal cord injury. Brain Res Bull 2010 Mar; 84(4–5): 306–16PubMed

77.

Brambilla R, Persaud T, Hu X, et al. Transgenic inhibition of astroglial NF-kappa B improves functional outcome in experimental autoimmune encephalomyelitis by suppressing chronic central nervous system inflammation. J Immunol 2009 Mar 1; 182(5): 2628–40PubMedCrossRef

78.

Hamby ME, Hewett JA, Hewett SJ. TGF-beta1 potentiates astrocytic nitric oxide production by expanding the population of astrocytes that express NOS-2. Glia 2006 Nov 1; 54(6): 566–77PubMedCrossRef

79.

Takano T, Kang J, Jaiswal JK, et al. Receptor-mediated glutamate release from volume sensitive channels in astrocytes. Proc Natl Acad Sci U S A 2005 Nov 8; 102(45): 16466–71PubMedCrossRef

80.

Rolls A, Shechter R, Schwartz M. The bright side of the glial scar in CNS repair. Nat Rev Neurosci 2009 Mar; 10(3): 235–41PubMedCrossRef

81.

Trendelenburg G, Dirnagl U. Neuroprotective role of astrocytes in cerebral ischemia: focus on ischemic preconditioning. Glia 2005 Jun; 50(4): 307–20PubMedCrossRef

82.

Kuhlmann T, Lassmann H, Bruck W. Diagnosis of inflammatory demyelination in biopsy specimens: a practical approach. Acta Neuropathol 2008 Mar; 115(3): 275–87PubMedCrossRef

83.

Voskuhl RR, Peterson RS, Song B, et al. Reactive astrocytes form scar-like perivascular barriers to leukocytes during adaptive immune inflammation of the CNS. J Neurosci 2009 Sep 16; 29(37): 11511–22PubMedCrossRef

84.

Thal DR, Schultz C, Dehghani F, et al. Amyloid beta-protein (Abeta)-containing astrocytes are located preferentially near N-terminal-truncated Abeta deposits in the human entorhinal cortex. Acta Neuropathol 2000 Dec; 100(6): 608–17PubMedCrossRef

85.

Faulkner JR, Herrmann JE, Woo MJ, et al. Reactive astrocytes protect tissue and preserve function after spinal cord injury. J Neurosci 2004 Mar 3; 24(9): 2143–55PubMedCrossRef

86.

Li L, Lundkvist A, Andersson D, et al. Protective role of reactive astrocytes in brain ischemia. J Cereb Blood Flow Metab 2008 Mar; 28(3): 468–81PubMedCrossRef

87.

Di Giorgio FP, Carrasco MA, Siao MC, et al. Non-cell autonomous effect of glia on motor neurons in an embryonic stem cell-based ALS model. Nat Neurosci 2007 May; 10(5): 608–14PubMedCrossRef

88.

Nagai M, Re DB, Nagata T, et al. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci 2007 May; 10(5): 615–22PubMedCrossRef

89.

McKerracher L, David S, Jackson DL, et al. Identification of myelin-associated glycoprotein as a major myelin-derived inhibitor of neurite growth. Neuron 1994 Oct; 13(4): 805–11PubMedCrossRef

90.

Mukhopadhyay G, Doherty P, Walsh FS, et al. A novel role for myelin-associated glycoprotein as an inhibitor of axonal regeneration. Neuron 1994 Sep; 13(3): 757–67PubMedCrossRef

91.

Chen MS, Huber AB, van der Haar ME, et al. Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. Nature 2000 Jan 27; 403(6768): 434–9PubMedCrossRef

92.

GrandPre T, Nakamura F, Vartanian T, et al. Identification of the Nogo inhibitor of axon regeneration as a reticulon protein. Nature 2000 Jan 27; 403(6768): 439–44PubMedCrossRef

93.

Prinjha R, Moore SE, Vinson M, et al. Inhibitor of neurite outgrowth in humans. Nature 2000 Jan 27; 403(6768): 383–4PubMedCrossRef

94.

Wang KC, Koprivica V, Kim JA, et al. Oligodendrocytemyelin glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth. Nature 2002 Jun 27; 417(6892): 941–4PubMedCrossRef

95.

Filbin MT. Myelin-associated inhibitors of axonal regeneration in the adult mammalian CNS. Nat Rev Neurosci 2003 Sep; 4(9): 703–13PubMedCrossRef

96.

Yiu G, He Z. Glial inhibition of CNS axon regeneration. Nat Rev Neurosci 2006 Aug; 7(8): 617–27PubMedCrossRef

97.

Mi S, Sandrock A, Miller RH. LINGO-1 and its role in CNS repair. Int J Biochem Cell Biol 2008; 40(10): 1971–8PubMedCrossRef

98.

Cao Z, Gao Y, Deng K, et al. Receptors for myelin inhibitors: structures and therapeutic opportunities. Mol Cell Neurosci 2010 Jan; 43(1): 1–14PubMedCrossRef

99.

Yang LJ, Zeller CB, Shaper NL, et al. Gangliosides are neuronal ligands for myelin-associated glycoprotein. Proc Natl Acad Sci U S A 1996 Jan 23; 93(2): 814–8PubMedCrossRef

100.

Vyas AA, Patel HV, Fromholt SE, et al. Gangliosides are functional nerve cell ligands for myelin-associated glycoprotein (MAG), an inhibitor of nerve regeneration. Proc Natl Acad Sci U S A 2002 Jun 11; 99(12): 8412–7PubMedCrossRef

101.

Atwal JK, Pinkston-Gosse J, Syken J, et al. PirB is a functional receptor for myelin inhibitors of axonal regeneration. Science 2008 Nov 7; 322(5903): 967–70PubMedCrossRef

102.

Goh EL, Young JK, Kuwako K, et al. Beta1-integrin mediates myelin-associated glycoprotein signaling in neuronal growth cones. Mol Brain 2008; 1(1): 10PubMedCrossRef

103.

Quarles RH. Myelin-associated glycoprotein (MAG): past, present and beyond. JNeurochem 2007 Mar; 100(6): 1431–48

104.

Schnaar RL, Lopez PH. Myelin-associated glycoprotein and its axonal receptors. J Neurosci Res 2009 Nov 15; 87(15): 3267–76PubMedCrossRef

105.

Bartsch U, Bandtlow CE, Schnell L, et al. Lack of evidence that myelin-associated glycoprotein is a major inhibitor of axonal regeneration in the CNS. Neuron 1995 Dec; 15(6): 1375–81PubMedCrossRef

106.

Lee JK, Geoffroy CG, Chan AF, et al. Assessing spinal axon regeneration and sprouting in Nogo-, MAG-, and OMgp-deficient mice. Neuron 2010 Jun 10; 66(5): 663–70PubMedCrossRef

107.

Yin X, Crawford TO, Griffin JW, et al. Myelin-associated glycoprotein is a myelin signal that modulates the caliber of myelinated axons. J Neurosci 1998 Mar 15; 18(6): 1953–62PubMed

108.

Nguyen T, Mehta NR, Conant K, et al. Axonal protective effects of the myelin-associated glycoprotein. J Neurosci 2009 Jan 21; 29(3): 630–7PubMedCrossRef

109.

Warrington AE, Bieber AJ, Van Keulen V, et al. Neuron-binding human monoclonal antibodies support central nervous system neurite extension. J Neuropathol Exp Neurol 2004 May; 63(5): 461–73PubMed

110.

Schnell L, Schwab ME. Axonal regeneration in the rat spinal cord produced by an antibody against myelin-associated neurite growth inhibitors. Nature 1990 Jan 18; 343(6255): 269–72PubMedCrossRef

111.

Brosamle C, Huber AB, Fiedler M, et al. Regeneration of lesioned corticospinal tract fibers in the adult rat induced by a recombinant, humanized IN-1 antibody fragment. J Neurosci 2000 Nov 1; 20(21): 8061–8PubMed

112.

Rodriguez M, Lennon VA, Benveniste EN, et al. Remyelination by oligodendrocytes stimulated by antiserum to spinal cord. J Neuropathol Exp Neurol 1987 Jan; 46(1): 84–95PubMedCrossRef

113.

Howe CL, Bieber AJ, Warrington AE, et al. Antiapoptotic signaling by a remyelination-promoting human anti-myelin antibody. Neurobiol Dis 2004 Feb; 15(1): 120–31PubMedCrossRef

114.

Miller DJ, Sanborn KS, Katzmann JA, et al. Monoclonal autoantibodies promote central nervous system repair in an animal model of multiple sclerosis. J Neurosci 1994 Oct; 14(10): 6230–8PubMed

115.

Warrington AE, Asakura K, Bieber AJ, et al. Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. Proc Natl Acad Sci U S A 2000 Jun 6; 97(12): 6820–5PubMedCrossRef

116.

Rodriguez M, Warrington AE, Pease LR. Invited article: human natural autoantibodies in the treatment of neurologic disease. Neurology 2009 Apr 7; 72(14): 1269–76PubMedCrossRef

117.

Casali P, Schettino EW. Structure and function of natural antibodies. Curr Top Microbiol Immunol 1996; 210: 167–79PubMedCrossRef

118.

Boes M. Role of natural and immune IgM antibodies in immune responses. Mol Immunol 2000 Dec; 37(18): 1141–9PubMedCrossRef

119.

Elkon K, Casali P. Nature and functions of autoantibodies. Nat Clin Pract Rheumatol 2008 Sep; 4(9): 491–8PubMedCrossRef

120.

Binder CJ. Natural IgM antibodies against oxidation-specific epitopes. J Clin Immunol 2010 May; 30 Suppl. 1: S56–60PubMedCrossRef

121.

Jeannin P, Jaillon S, Delneste Y. Pattern recognition receptors in the immune response against dying cells. Curr Opin Immunol 2008 Oct; 20(5): 530–7PubMedCrossRef

122.

Vollmers HP, Brandlein S. Natural antibodies and cancer. J Autoimmun 2007 Dec; 29(4): 295–302PubMedCrossRef

123.

Watzlawik J, Holicky E, Edberg DD, et al. Human remyelination promoting antibody inhibits apoptotic signaling and differentiation through Lyn kinase in primary rat oligodendrocytes. Glia 2010 Nov 15; 58(15): 1782–93PubMedCrossRef

Titel: Enhancing CNS Repair in Neurological Disease
Challenges Arising from Neurodegeneration and Rewiring of the Network
verfasst von: Xiaohua Xu
Arthur E. Warrington
Allan J. Bieber
Moses Rodriguez
Publikationsdatum: 01.07.2011
Verlag: Springer International Publishing
Erschienen in: CNS Drugs / Ausgabe 7/2011
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI: https://doi.org/10.2165/11587830-000000000-00000

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2011

Rituximab for Secondary Progressive Multiple Sclerosis

Vilazodone

Long-Term Outcomes with Medications for Attention-Deficit Hyperactivity Disorder

Pharmacological Management of Treatment-Resistant Obsessive-Compulsive Disorder

Issues in the Management of Challenging Behaviours of Adults with Autism Spectrum Disorder